Related Experiment Video
Updated: May 26, 2026
08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Cell-type-dependent thyroid hormone effects on glioma tumor cell lines
Alexandros Liappas1, Liappas Alexandros, Iordanis Mourouzis
1Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue,11527 Goudi, Athens, Greece.
Journal of Thyroid Research
|January 10, 2012
Summary
Triiodothyronine (T3) can re-differentiate glioma cells. Its effect on proliferation varies by tumor type, with aggressive tumors showing increased sensitivity, potentially linked to the thyroid hormone receptor alpha 1 (TRα1).
Area of Science:
- Neuroscience
- Endocrinology
- Oncology
Background:
- Thyroid hormone's role in development suggests therapeutic potential.
- Understanding thyroid hormone action in glioma is crucial.
Purpose of the Study:
- Investigate long-term triiodothyronine (T3) effects on glioma cell lines.
- Determine T3's impact on glioma cell proliferation and differentiation.
Main Methods:
- Exposed 1321N1 (astrocytoma) and U87MG (glioblastoma) cells to T3.
- Analyzed cell proliferation, differentiation, and receptor expression (TRα1, TRβ1).
- Assessed T3-induced kinase signaling pathways (ERK, Akt).
Main Results:
- T3 promoted re-differentiation in both cell lines.
- T3 increased proliferation in 1321N1 (short-term) but suppressed it in U87MG.
- U87MG showed a 2.9-fold increase in TRα1 expression compared to 1321N1.
- T3 increased phospho-Akt levels in 1321N1 cells.
Conclusions:
- T3 re-differentiates glioma cells.
- T3's antiproliferative effect is tumor-type dependent; aggressive gliomas are more sensitive.
- Thyroid hormone receptor alpha 1 (TRα1) may mediate T3's effects in glioma.
